Dordaviprone: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Dordaviprone. Educational only — not medical advice.
Labeled uses
MODEYSO is indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Source: FDA labeling via NIH DailyMed (set ad45b43e…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.